Affiliation:
1. RAND Corporation , Arlington , USA
Abstract
Abstract
Pre-Exposure Prophylaxis (PrEP) is a drug that, as demonstrated in clinical trials, when taken makes the user virtually immune to HIV. This has led to numerous countries making the drug available, but little is known about the population level effects of PrEP. Using panel data from 40 European countries I study the effect of countries adopting WHO recommendations to make PrEP available to citizens. I demonstrate that PrEP availability leads to around 15–20 % fewer new HIV infections. My results indicate that PrEP can be an effective tool in reducing HIV incidence.
Subject
Economics, Econometrics and Finance (miscellaneous),Economics and Econometrics
Reference14 articles.
1. Bertrand, M., E. Duflo, and S. Mullainathan. 2004. “How Much Should We Trust Differences-In-Differences Estimates?” Quarterly Journal of Economics 119 (1): 249–75. https://doi.org/10.1162/003355304772839588.
2. CDC. 2022a. PrEP Effectiveness. Also available at: https://www.cdc.gov/hiv/basics/prep/prep-effectiveness.html.
3. CDC. 2022b. HIV Cost-Effectiveness. Also available at: https://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html#:∼:text=Currently%2C%20the%20lifetime%20treatment%20cost,than%20%24379%2C668%20per%20infection%20averted.
4. Estcourt, C., A. Yeung, R. Nandwani, D. Goldberg, B. Cullen, N. Steedman, L. Wallace, and S. Hutchinson. 2021. “Population-level Effectiveness of a National HIV Preexposure Prophylaxis Programme in MSM.” AIDS 35 (4): 665–73, https://doi.org/10.1097/QAD.0000000000002790.
5. Goodman-Bacon, A. 2021. “Difference-in-differences with Variation in Treatment Timing.” Journal of Econometrics 225 (2): 254–77. https://doi.org/10.1016/j.jeconom.2021.03.014.